| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.04 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.098 | 0.04 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.34 | 0.05 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |